obesity drugs

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Vivani Medical, Inc. (NASDAQ:VANI) and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Financial terms of the expanded agreement were not...

In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly & Co. (NYSE:LLY) has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound. What Happened: The investment is aimed at ensuring a...

Vivani Medical Inc. (NASDAQ:VANI) expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024. The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or...

An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drugs, Wegovy and Ozempic, continue their treatment after two years. The data provided to Reuters highlights a significant decline in long-term adherence to...

The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone. What Happened: The WHO has warned that the use of effective and popular obesity medications will not be...

In a recent announcement, Eli Lilly and Co (NYSE:LLY) has projected a significant revenue increase for 2024, driven by the demand for its diabetes and obesity drugs. What Happened: The pharmaceutical giant anticipates a 20% rise in sales, propelling its revenues to over $40 billion, reported the...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless...

Stocks in the food and beverage industry experienced their most challenging week since May 2022, further extending the declines seen in the preceding weeks. The First Trust Nasdaq Food & Beverage ETF (NYSE:FTXG) plummeted by over 5% this week, marking its third consecutive week of losses and...